| Literature DB >> 26622640 |
Chong Teng1, L I Li1, Weixi Shen1, Jingang Li2, Ying Liu1, Qiuying Jiang1, Tao Xin1, Dayong Huang1, Xiaowei Song1, Yanju Lv1, Yinghua Jin1.
Abstract
Synovial sarcoma is a rare, highly malignant soft-tissue tumor that occurs primarily in the extremities. At present, there is no effective clinical treatment for this condition. The present study reports the case of a 49-year-old male who was diagnosed with pleural synovial sarcoma and treated with recombinant human endostatin (Endostar) combined with chemotherapy for a total of six cycles, followed by sunitinib maintenance therapy. To the best of our knowledge, this is the first reported use of sunitinib for maintenance therapy in pleural synovial sarcoma. The patient survived for 25 months after the recurrence of the disease following surgery. The results indicate that this combination therapy was effective in the treatment of pleural synovial sarcoma. The present study also briefly reviews the literature on pleural synovial sarcoma, and the features and treatments for this rare case are discussed.Entities:
Keywords: Endostar; chemotherapy; pleura; sunitinib; synovial sarcoma
Year: 2015 PMID: 26622640 PMCID: PMC4509089 DOI: 10.3892/ol.2015.3311
Source DB: PubMed Journal: Oncol Lett ISSN: 1792-1074 Impact factor: 2.967